General – Page 33 – Cannabis Industry

September 13, 2018 by Duane Morris

Duane Morris’ Michael Schwamm to Present on Investing in the Cannabis Industry

Duane Morris partner Michael Schwamm will present on “Investing in the Cannabis Industry” at the Opal Group Family Office & Private Wealth Management Forum West on October 25, 2018, in Napa, California.

Known for the fastest growing population of newly structured family offices in the world, Northern California is largely dominated by first and second-generation families from the Silicon Valley. Investment strategies such as Private Equity, Venture Capital, and Technology will be familiar themes throughout this conference. Investment managers and families will come together to discuss the foundations in which they built their wealth, and uncork the various investment strategies in which to keep their portfolios growing. For more information, visit the Opal Group website.

September 13, 2018September 13, 2018 by Duane Morris

Duane Morris’ Jerome Levy to Discuss Municipal Regulation of Marijuana

Duane Morris partner Jerome Levy will participate in the Strafford webinar, “Municipal Regulation of Marijuana: Guidance on Permitting, Licensing and Zoning for Medical and Recreational Uses,” on Wednesday, October 10, 2018, from 1:00 p.m. to 2:30 p.m. (Eastern time).

This CLE webinar will offer guidance to local government lawyers on regulating cannabis consumption for medical and recreational uses. The panel will discuss the patchwork of current regulatory efforts across the country and explore some of the most effective strategies for regulating in municipalities based on current case law and the interplay with state and federal regulation. For more information and to register, visit the Strafford website.

September 4, 2018 by Duane Morris

Cannabis Patents: Patent Litigation in an Emerging U.S. Industry

Even though cannabis remains a Schedule I controlled substance under U.S. federal law, the United States Patent Office (USPTO), a federal agency of the U.S. Department of Commerce, routinely grants patents covering cannabis-related technologies. The Schedule I classification of cannabis is not relevant to patentability. As with any other invention, to be patentable, a cannabis-related invention must be new, useful, and nonobvious, and teach one of ordinary skill in the art how to make and use the invention. The USPTO has determined that many cannabis-related patent applications have met these requirements. Patents granted to cannabis-related inventions cover an enormous range of technologies, including cannabis plants, growing systems, extracts, methods of making extracts, foodstuffs, veterinary products, and methods of treating various diseases and disorders.

To read the full text of this article by Duane Morris attorney Gretchen L. Temeles, Ph.D., please visit the Cannabis Law Journal website.

August 21, 2018 by David E. Landau

Bank Closes Campaign Account of Pro-Cannabis Candidate

Banking continues to be a challenge for the cannabis industry. But, Wells Fargo recently erected a new barrier: It closed the campaign bank account of Nikki Fried, candidate for Agriculture Commissioner of Florida. According to a report in the New York Times on August 21, 2018, the bank took notice of the candidate’s advocacy for better access to medical marijuana. It then asked the campaign whether it accepted contributions from lobbyists for the medical marijuana industry. When the campaign replied it accepted contributions from executives and employees in the industry, Wells Fargo closed the account. The campaign now banks at BB&T. Full New York Times Story

August 16, 2018 by Seth A. Goldberg

Constellation Brands’ $4B Cannabis Investment

On August 15, 2018, Constellation Brands, which owns popular beer, wine and spirits products, such as Corona, Robert Mondavi and High West, announced it is investing $4 billion in Canopy Growth, which is one of the leading investors in the global legal cannabis market. The announcement boosted Cannabis market stocks in the US and Canada, and is likely to catch the eye of big alcohol, big tobacco, big pharma and larger consumer products companies that have been interested in entering the growing legal marijuana markets. More and more companies once-hesitant about doing so are finding that good counsel can help them navigate the regulatory hurdles that might otherwise stand in the way of profiting from this exciting market.

July 26, 2018 by Duane Morris

“Cannabis 107” Webinar Replay Available

A video replay of the webinar “Cannabis 107: The U.S. and Canadian Cannabis Markets: 2018 Mid-Year Review” is available to view.

June 29, 2018July 2, 2018 by Seth A. Goldberg

Momentum Builds With Schumer’s Bill To Legalize Marijuana

Just weeks after Senators Elizabeth Warren (D-Mass) and Cory Gardner (R-Colo) introduced bi-partisan legislation to make marijuana lawful under a state’s marijuana laws also lawful under the Controlled Substances Act (CSA), Senate Minority Leader Chuck Schumer (D-NY) introduced legislation removing marijuana from the CSA altogether on Wednesday, June 27. Schumer’s bill also comes just one day after Oklahoman’s passed legislation legalizing medical marijuana in their traditionally red state, and one day before the U.S. Senate passed legislation legalizing hemp for all purposes, including extracts from hemp, such as cannabidiol.

By removing from the purview of the CSA, state-legal cannabis and proceeds derived therefrom, the Warren/Gardner legislation, if passed, would likely have the effect of nationwide legalization, but state operators and consumers would still need to be concerned about marijuana’s Schedule 1 status under the CSA, whereas the Schumer bill, if passed, would eliminate those concerns by removing marijuana from the CSA.

June 27, 2018 by Duane Morris

Pennsylvania Legislature Rescues Medical Marijuana Clinical Research Program

By David Landau

On Friday June 22nd, Pennsylvania Governor Tom Wolf signed into law a bill allowing Pennsylvania’s Medical Marijuana clinical research program to proceed. A Pennsylvania court a short while ago enjoined the program. Continue reading “Pennsylvania Legislature Rescues Medical Marijuana Clinical Research Program”

June 21, 2018 by Duane Morris

“Cannabis 106” Webinar Replay Available

A video replay of the webinar “Cannabis 106: Banking and Financing in the Cannabis Industry” is available to view.

June 12, 2018April 6, 2020 by Justin A. Santarosa

California Department of Public Health’s Re-Adopted Emergency Regulations

The California Department of Public Health (CDPH) is the state agency designated under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) as responsible for regulating cannabis manufacturing.

The CDPH issued emergency regulations for manufacturers in November 2017, and has now proposed readopting those regulations for another 180 days. Based on feedback from the public and stakeholders in the industry, the CDPH has proposed some changes to these regulations.

This blog post will highlight the changes to the CDPH emergency regulations and identify key issues for manufacturers. In separate posts, we will be describing the changes made by the California Department of Food and Agriculture and the California Bureau of Cannabis Control.

Changes to Emergency Regulations:

The CDPH has removed the distinction of A and M Licenses and now only requires one application and applicants will only have to pay one licensing fee. Previously you had to submit two applications and pay two separate licensing fees if you wanted to operate in the medicinal and adult-use market.
The readopted regulations have now incorporated the previously released shared-use facility regulations, which allow a manufacturing premises to be used my multiple businesses that take turns utilizing the space and equipment. This allows for operations similar to a commercial kitchen or agreements in which larger manufacturers offer space and use of equipment to smaller manufacturers.
The CDPH has removed tinctures from the definition of a product containing more than 0.5% alcohol by volume. However, tinctures cannot be sold in a package larger than two fluid ounces and shall include a calibrated dropper or other measuring device

The change to only a single application for both medical and adult-use is a welcome change for manufacturing businesses. Overall, the CDPH did not make significant changes to its regulations.

If you have any questions about the regulations, please contact Justin Santarosa in our Los Angeles office.